These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 17763218)

  • 1. Prognostic value of p53, Ki-67, microstaging and microvessel density in pT1G3 bladder tumors: creation of risk groups for progression.
    Queipo-Zaragoza JA; Ruiz-Cerda JL; Vera-Donoso CD; Vera-Sempere F; Budia-Alba A; Jimenez-Cruz JF
    Scand J Urol Nephrol; 2007; 41(4):283-9. PubMed ID: 17763218
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic significance of p53, bcl-2 and Ki-67 in high risk superficial bladder cancer.
    Stavropoulos NE; Filiadis I; Ioachim E; Hastazeris K; Tsimaris I; Kalogeras D; Stefanaki S; Agnantis NJ
    Anticancer Res; 2002; 22(6B):3759-64. PubMed ID: 12552989
    [TBL] [Abstract][Full Text] [Related]  

  • 3. p53 expression compared with other prognostic factors in OMS grade-I stage-Ta transitional cell carcinoma of the bladder.
    Casetta G; Gontero P; Russo R; Pacchioni D; Tizzani A
    Eur Urol; 1997; 32(2):229-36. PubMed ID: 9286659
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of cell cycle proteins in T1a and T1b urothelial bladder carcinoma and their value in predicting tumor progression.
    Mhawech P; Greloz V; Oppikofer C; Szalay-Quinodoz I; Herrmann F
    Cancer; 2004 Jun; 100(11):2367-75. PubMed ID: 15160340
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationship of tumor angiogenesis and nuclear p53 accumulation in invasive bladder cancer.
    Bochner BH; Esrig D; Groshen S; Dickinson M; Weidner N; Nichols PW; Skinner DG; Cote RJ
    Clin Cancer Res; 1997 Sep; 3(9):1615-22. PubMed ID: 9815851
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic value of molecular markers, sub-stage and European Organisation for the Research and Treatment of Cancer risk scores in primary T1 bladder cancer.
    van Rhijn BW; Liu L; Vis AN; Bostrom PJ; Zuiverloon TC; Fleshner NE; van der Aa MN; Alkhateeb SS; Bangma CH; Jewett MA; Zwarthoff EC; Bapat B; van der Kwast TH; Zlotta AR
    BJU Int; 2012 Oct; 110(8):1169-76. PubMed ID: 22448597
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protein expression patterns of ezrin are predictors of progression in T1G3 bladder tumours treated with nonmaintenance bacillus Calmette-Guérin.
    Palou J; Algaba F; Vera I; Rodriguez O; Villavicencio H; Sanchez-Carbayo M
    Eur Urol; 2009 Nov; 56(5):829-36. PubMed ID: 18926620
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Does the expression of fascin-1 and tumor subclassification help to assess the risk of recurrence and progression in t1 urothelial urinary bladder carcinoma?
    Soukup V; Babjuk M; Dusková J; Pesl M; Szakáczová M; Zámecník L; Dvorácek J
    Urol Int; 2008; 80(4):413-8. PubMed ID: 18587253
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Prognostic value of the immunohistochemical expression of: Ki67, p53, PCNA and Bcl2 in the superficial tumors of the bladder].
    Rammeh-Rommani S; Zermani R; Sfaxi M; Chabchoub A; Zouari B; Ayed M; Ben Jilani-Baltagi S
    Tunis Med; 2007 Jun; 85(6):509-12. PubMed ID: 17644907
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The predictive value of p53, p27(kip1), and alpha-catenin for progression in superficial bladder carcinoma.
    Schrier BP; Vriesema JL; Witjes JA; Kiemeney LA; Schalken JA
    Eur Urol; 2006 Jul; 50(1):76-82. PubMed ID: 16413663
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bladder sparing approach for initial T1G3 bladder cancer: Do multifocality, size of tumor or concomitant carcinoma in situ matter? A long-term analysis of 132 patients.
    Denzinger S; Otto W; Fritsche HM; Roessler W; Wieland WF; Hartmann A; Burger M
    Int J Urol; 2007 Nov; 14(11):995-9; discussion 999. PubMed ID: 17956523
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proliferative status is a risk index for recurrence in primary superficial (pTa/T1) low-grade urothelial bladder carcinoma.
    Su JS; Arima K; Hasegawa M; Franco OE; Yanagawa M; Sugimura Y; Kawamura J
    Hinyokika Kiyo; 2003 Nov; 49(11):649-58. PubMed ID: 14719452
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Implications of prognostic markers in brain tumors.
    Grzybicki DM; Moore SA
    Clin Lab Med; 1999 Dec; 19(4):833-47. PubMed ID: 10572718
    [TBL] [Abstract][Full Text] [Related]  

  • 14. E-cadherin immunoreactivity correlates with recurrence and progression of minimally invasive transitional cell carcinomas of the urinary bladder.
    Mahnken A; Kausch I; Feller AC; Krüger S
    Oncol Rep; 2005 Oct; 14(4):1065-70. PubMed ID: 16142373
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multiplicity and history have a detrimental effect on survival of patients with T1G3 bladder tumors selected for conservative treatment.
    Serretta V; Ruggirello A; Dispensa N; Allegro R; Aragona F; Melloni D
    J Urol; 2008 Sep; 180(3):886-90; discussion 891. PubMed ID: 18635223
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nuclear DNA content, an adjunct to p53 and Ki-67 as a marker of resistance to radiation therapy in oral cavity and pharyngeal squamous cell carcinoma.
    Raybaud H; Fortin A; Bairati I; Morency R; Monteil RA; Têtu B
    Int J Oral Maxillofac Surg; 2000 Feb; 29(1):36-41. PubMed ID: 10691142
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Bladder preservation or initial cystectomy in T1G3 bladder cancer: which parameters help in therapeutic decision-making?].
    Denzinger S; Burger M; Fritsche HM; Ganzer R; Blana A; Wieland WF; Otto W
    Aktuelle Urol; 2008 Jan; 39(1):58-61; discussion 62-3. PubMed ID: 18228189
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic factors in stage T1 bladder cancer: tumor pattern (solid or papillary) and vascular invasion more important than depth of invasion.
    Andius P; Johansson SL; Holmäng S
    Urology; 2007 Oct; 70(4):758-62. PubMed ID: 17991551
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The expression level of ligands for natural killer cell receptors predicts response to bacillus Calmette-Guerin therapy: a pilot study.
    Yutkin V; Pode D; Pikarsky E; Mandelboim O
    J Urol; 2007 Dec; 178(6):2660-4. PubMed ID: 17945285
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The abnormalities in the p53/p21WAF1 pathway have a significant role in the pathogenesis and progression of gastrointestinal stromal tumors.
    Chou YP; Lin JW; Wang CC; Chiu YC; Huang CC; Chuah SK; Tai MH; Yi LN; Lee CM; Changchien CS; Hu TH
    Oncol Rep; 2008 Jan; 19(1):49-56. PubMed ID: 18097575
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.